These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9123690)

  • 41. Perioperative chemotherapy in muscle-invasive bladder cancer: overview and the unmet clinical need for alternative adjuvant therapy as studied in the MAGNOLIA trial.
    Colombel M; Heidenreich A; Martínez-Piñeiro L; Babjuk M; Korneyev I; Surcel C; Yakovlev P; Colombo R; Radziszewski P; Witjes F; Schipper R; Mulders P; Witjes WP
    Eur Urol; 2014 Mar; 65(3):509-11. PubMed ID: 24268503
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Endoscopic operations in invasive cancer of the urinary bladder].
    Martov AG; Chernyshev IV; Sysoev PA; Gushchin BL; Shapovalov VV; Kozlov VV; Kornienko SI
    Urologiia; 2005; (2):35-9. PubMed ID: 15989025
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
    Evans CP
    Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
    [No Abstract]   [Full Text] [Related]  

  • 44. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer.
    Clark PE
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):821-30. PubMed ID: 19496719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bladder cancer.
    Ozen H
    Curr Opin Oncol; 1998 May; 10(3):273-8. PubMed ID: 9619365
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Defining optimal therapy for muscle invasive bladder cancer.
    Herr HW; Dotan Z; Donat SM; Bajorin DF
    J Urol; 2007 Feb; 177(2):437-43. PubMed ID: 17222605
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
    Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
    Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aggressive management of elderly patients with muscle-invasive bladder cancer.
    Weizer AZ; Montie JE; Lee CT
    Nat Clin Pract Urol; 2006 Jul; 3(7):346-7. PubMed ID: 16835604
    [No Abstract]   [Full Text] [Related]  

  • 50. Endpoints of clinical trials in invasive bladder cancer.
    Tannock IF
    Semin Oncol; 1990 Oct; 17(5):619-27. PubMed ID: 2218575
    [No Abstract]   [Full Text] [Related]  

  • 51. Prognostic factors in infiltrating bladder cancer.
    Richards B; Aso Y; Bollack C; Fossa S; Koontz W; Matsuda M; Matsumoto K; Prout G; Van der Werf-Messing B; Wolf H
    Prog Clin Biol Res; 1986; 221():271-86. PubMed ID: 3543944
    [No Abstract]   [Full Text] [Related]  

  • 52. Editorial comment.
    Smith AB; Pruthi RS
    Urology; 2010 Feb; 75(2):398. PubMed ID: 20152492
    [No Abstract]   [Full Text] [Related]  

  • 53. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a new standard of care?
    Feneley MR; Harland S
    BJU Int; 2003 Dec; 92(9):877-8. PubMed ID: 14632837
    [No Abstract]   [Full Text] [Related]  

  • 54. Editorial comment.
    Weizer AZ
    J Urol; 2010 Mar; 183(3):920. PubMed ID: 20083283
    [No Abstract]   [Full Text] [Related]  

  • 55. Optimizing Clinical Trial Design for Patients with Non-muscle-invasive Bladder Cancer.
    Weinstock C; Agrawal S; Chang E
    Eur Urol; 2022 Jul; 82(1):47-48. PubMed ID: 35304001
    [No Abstract]   [Full Text] [Related]  

  • 56. Increasing incidence, but stable mortality, of bladder cancer in Ontario. Analysis of a population sample.
    Jewett MA; Pereira G; Nijmeh P; Herschorn S; Honey RJ; Struthers NW; Bruce AW; Barkin M
    Urology; 1991; 37(5 Suppl):4-7. PubMed ID: 2021033
    [No Abstract]   [Full Text] [Related]  

  • 57. Re: Emilio Bria, Enzo Maria Ruggeri, Edmondo Terzoli, Francesco Cognetti, Camillo Francesco Pollera and Diana Giannarelli. Adjuvant chemotherapy for bladder cancer: the chance for meta-analyses comparison. Eur Urol 2007;51:576-7.
    Vale C; Stewart L; Tierney J
    Eur Urol; 2007 Feb; 51(2):577-8. PubMed ID: 16854518
    [No Abstract]   [Full Text] [Related]  

  • 58. Bladder cancer: Elderly and female patients fare the worst and deserve better.
    Witjes JA
    Nat Rev Urol; 2013 Jul; 10(7):371-2. PubMed ID: 23774957
    [No Abstract]   [Full Text] [Related]  

  • 59. Does age really matter in the choice of treatment for bladder cancer?
    Dal Moro F; Rossi A; Zattoni F
    Br J Cancer; 2013 Jun; 108(11):2415-6. PubMed ID: 23674087
    [No Abstract]   [Full Text] [Related]  

  • 60. [Survival analysis using SAS software package].
    Liu WW; Hu LP
    Zhong Xi Yi Jie He Xue Bao; 2010 May; 8(5):489-93. PubMed ID: 20456850
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.